149 related articles for article (PubMed ID: 21664851)
21. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
22. SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer.
Vaz J; Ansari D; Sasor A; Andersson R
Pancreas; 2015 Oct; 44(7):1024-35. PubMed ID: 26335014
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
[TBL] [Abstract][Full Text] [Related]
24. Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose.
Wilkowski R; Thoma M; Weingandt H; Dühmke E; Heinemann V
JOP; 2005 May; 6(3):216-30. PubMed ID: 15883472
[TBL] [Abstract][Full Text] [Related]
25. Molecular signatures of pancreatic cancer.
Hong SM; Park JY; Hruban RH; Goggins M
Arch Pathol Lab Med; 2011 Jun; 135(6):716-27. PubMed ID: 21631264
[TBL] [Abstract][Full Text] [Related]
26. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer.
Wei L; Ye H; Li G; Lu Y; Zhou Q; Zheng S; Lin Q; Liu Y; Li Z; Chen R
Cell Death Dis; 2018 Oct; 9(11):1065. PubMed ID: 30337520
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.
Sarvepalli D; Rashid MU; Rahman AU; Ullah W; Hussain I; Hasan B; Jehanzeb S; Khan AK; Jain AG; Khetpal N; Ahmad S
Crit Rev Oncog; 2019; 24(2):199-212. PubMed ID: 31679214
[TBL] [Abstract][Full Text] [Related]
28. PANDA cyst-fluid analysis: eats, shoots and leaves?
Anderson MA; Kwon RS; Scheiman JM
Gastrointest Endosc; 2009 May; 69(6):1103-5. PubMed ID: 19410042
[No Abstract] [Full Text] [Related]
29. PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
Schönleben F; Qiu W; Remotti HE; Hohenberger W; Su GH
Langenbecks Arch Surg; 2008 May; 393(3):289-96. PubMed ID: 18343945
[TBL] [Abstract][Full Text] [Related]
30. Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs).
Koorstra JB; Feldmann G; Habbe N; Maitra A
Langenbecks Arch Surg; 2008 Jul; 393(4):561-70. PubMed ID: 18283486
[TBL] [Abstract][Full Text] [Related]
31. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
[TBL] [Abstract][Full Text] [Related]
32. Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function.
Tomimaru Y; Eguchi H; Iwagami Y; Akita H; Noda T; Gotoh K; Kobayashi S; Nagano H; Mori M; Doki Y
Cancer Chemother Pharmacol; 2020 Mar; 85(3):537-545. PubMed ID: 31834436
[TBL] [Abstract][Full Text] [Related]
33. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas.
Izeradjene K; Combs C; Best M; Gopinathan A; Wagner A; Grady WM; Deng CX; Hruban RH; Adsay NV; Tuveson DA; Hingorani SR
Cancer Cell; 2007 Mar; 11(3):229-43. PubMed ID: 17349581
[TBL] [Abstract][Full Text] [Related]
34. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Seufferlein T; Bachet JB; Van Cutsem E; Rougier P;
Ann Oncol; 2012 Oct; 23 Suppl 7():vii33-40. PubMed ID: 22997452
[No Abstract] [Full Text] [Related]
35. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
36. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA
Cancer Res; 2007 Sep; 67(17):8121-30. PubMed ID: 17804724
[TBL] [Abstract][Full Text] [Related]
37. FAM84B, amplified in pancreatic ductal adenocarcinoma, promotes tumorigenesis through the Wnt/β-catenin pathway.
Zhang X; Xu J; Yan R; Zhang Y; Hu Z; Fu H; You Q; Cai Q; Yang D
Aging (Albany NY); 2020 Apr; 12(8):6808-6822. PubMed ID: 32291380
[TBL] [Abstract][Full Text] [Related]
38. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
Calabretta S; Bielli P; Passacantilli I; Pilozzi E; Fendrich V; Capurso G; Fave GD; Sette C
Oncogene; 2016 Apr; 35(16):2031-9. PubMed ID: 26234680
[TBL] [Abstract][Full Text] [Related]
39. HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.
Maréchal R; Van Laethem JL
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1439-41. PubMed ID: 19828005
[TBL] [Abstract][Full Text] [Related]
40. Cancer. Breaching the cancer fortress.
Olson P; Hanahan D
Science; 2009 Jun; 324(5933):1400-1. PubMed ID: 19520948
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
